BioArctic AB (publ) (BRCTF PINK) stock market data APIs
$19.62
0.02(0.1%)
as of January 24, 2025
BioArctic AB (publ) Financial Data Overview
Price chart is built with
Anychart
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Prev. Close
19.6
Open
19.62
Volume
1 150
High
19.62
Low
19.6
52 wk Range
12.9435-23.75
Market Cap
1 605 M
Shares Outstanding
73 989 K
Revenue
299 M
EPS
-0.0213
Beta
-0.25
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioArctic AB (publ) data using free add-ons & libraries
Get BioArctic AB (publ) Fundamental Data
BioArctic AB (publ) Fundamental data includes:
- Net Revenue: 299 M
- EBITDA: -74 368 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-14
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioArctic AB (publ) News
New
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM, Jan. 14, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologi...
High Growth Tech Stocks To Watch In January 2025
As we enter January 2025, global markets have shown mixed performances with the U.S. stock indices closing out a strong year despite recent fluctuations, while economic indicators such as the Chicago ...
3 Swedish Growth Stocks With Up To 34% Insider Ownership
In recent weeks, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising amid hopes for quicker interest rate cuts by the ECB and potential economic stimulus from C...
3 Swedish Growth Stocks With High Insider Ownership Expecting Up To 98% Earnings Growth
As European markets show signs of optimism with the pan-European STOXX Europe 600 Index climbing amid hopes for quicker interest rate cuts, Sweden's growth stocks are drawing attention for their poten...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
